Sesen Bio Inc (SESN)

NASDAQ
4.25
+0.07(+1.67%)
After Hours
4.22
-0.03(-0.7059%)
- Real-time Data
  • Volume:
    4,066,507
  • Bid/Ask:
    4.21/4.24
  • Day's Range:
    4.11 - 4.285

SESN Overview

Prev. Close
4.18
Day's Range
4.11-4.285
Revenue
15.55M
Open
4.279
52 wk Range
0.662-4.315
EPS
-0.9
Volume
4,066,507
Market Cap
736.47M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,738,172
P/E Ratio
-
Beta
0.85
1-Year Change
473.63%
Shares Outstanding
173,287,287
Next Earnings Date
Aug 16, 2021
What is your sentiment on Sesen Bio Inc?
or
Market is currently closed. Voting is open during market hours.

Sesen Bio Inc News

Sesen Bio Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuyStrong Buy
SummarySellStrong BuyStrong BuyStrong BuyStrong Buy

Sesen Bio Inc Company Profile

Sesen Bio Inc Company Profile

Employees
27

Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.

Read More
  • probaable correction
    0
    • https://www.businesswire.com/news/home/20210601005318/en/Sesen-Bio-Strengthens-Senior-Leadership-Team
      0
      • waiting for Vicineum™ approval (in the US in August 2021)
        0
    • breaking upper TL wedge
      0
      • breaking resistance again !!!
        1
        • Let’s see... hope it goes on
          0
      • good rocket day
        0
        • Stockholders meeting, May 3, 2021 - Proposal to increase shares of common stock by 200 million shares
          2
          • :( do you know what should be the price??
            0
          • Are you sure ? Do you habe link ? Or are you short seller ?
            0
        • Sesen Bio (Nasdaq: SESN), [...], announced that on Friday, March 5, 2021 the Company submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Vicineum1 for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) under the EMA’s centralized procedure.
          0
          • Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conference call with Dr. Neal Shore, medical director of the Carolina Urologic Research Center who will provide a clinical perspective on Vicineum, Sesen Bio’s product candidate for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition, members of the management team will provide a corporate update. The conference call is scheduled for Monday, March 15, 2021 at 8:00 a.m. ET.
            0
            • SESEN BIO INC looking bullish symmetrical triangle pattern and already breakout on monday. Price also above MA20.WEEKLY Chart looking cup and handle. Vanguards, Morgan Stanley, blackrock and Renaissance Technologies bought this stock, i looking something special have this stock. Small company but big investment coming. **Remember that Im not a broker or financial advisor, always do your own Due Diligence on every play.TAYOR (Take At You Own Risk)
              0
              • Go go fly sesen
                0
                • Sesen Bio's (SESN) Vicinium May Benefit From Manufacturing Issues Of Competing Drug | Seeking Alpha (copy and paste into google my link wont work) - Good news more trouble for Ferring. Should see a nice bounce fro SESN this week!
                  0
                  • Stock goes to 10+ in 2 Q
                    0
                    • With Priority Review, the anticipated target Prescription Drug User Fee Act (PDUFA) date for a decision on the BLA is August 18, 2021.
                      0
                      • Whats your price target on this guys?
                        0
                        • For the FDA approval in 2/3 weeks 5$ target. Then with sales of vicineum who knows where it can go.
                          0
                        • Iván SánchezAgree, this stock is strong
                          0
                        • 0
                      • Just buy and be patient guys!
                        0
                        • lol
                          1
                          • sorry not approval, FDA has granted priority review... meaning shorter review period for approval instead of the standard 6 to 10months period
                            2
                            • FDA approval obtained https://seekingalpha.com/pr/18192793-sesen-bio-announces-fda-acceptance-and-priority-review-of-biologics-license-application-for
                              1
                              • $4 today???
                                0
                                • Easy
                                  0
                                • Any news or just speculative play
                                  0
                              • Tnq for discount :)
                                0
                                • After so many green days, one red is ok
                                  0
                                  • One off these days it will break out
                                    0
                                    • 2.98 towards 3.25
                                      0
                                      • it will fly with the approval from FDA and it seems 80% possibility.
                                        0
                                        • The Company expects to learn if the BLA is accepted for filing by the FDA on February 16, 2021. If the file is accepted, in the following two to four weeks, the Company expects to receive a decision on the following three items:Priority vs. Standard reviewTarget PDUFA date for approvalNecessity of an FDA Advisory Committee meeting
                                          0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.